MedTrace Logo

Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor

NCT07203846 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-10-02

No results posted yet for this study

Summary

The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.

Conditions

  • ACS - Acute Coronary Syndrome
  • Ticagrelor
  • Microbiota
  • Platelet Aggregation
  • Myocardial Infarction (MI)
  • Blood Platelets
  • Drug Effects
  • Platelet Aggregation Inhibitors
  • Drug Resistance
  • Platelet Function Tests
  • Dysbiosis
  • Anti-Bacterial Agents
  • Rifaximin

Interventions

DRUG

Rifaximin

Participants receiving a 7-day course of oral rifaximin 400 mg every 12 hours

Sponsors & Collaborators

  • Ministry of Science and Higher Education, Poland

    collaborator OTHER_GOV

  • Collegium Medicum w Bydgoszczy

    lead OTHER

Principal Investigators

  • Jacek Kubica, Prof. · Collegium Medicum w Bydgoszczy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07203846 on ClinicalTrials.gov